Knowing that hormone receptor-positive, HER2-negative BC is generally a tumor with less immunoactivity, it is of interest whether the addition of checkpoint inhibitors, which usually trigger immune response, is feasible and effective in BC patients under CDK4/6i treatment. Here, NR4A1 is linked to breast cancer.